Related Experiment Video
Updated: Mar 29, 2026
Extrahepatic Bile Duct and Gall Bladder Dissection in Nine-Day-Old Mouse Neonates
Published on: August 23, 2022
Insights
Newborn screening for biliary atresia (a liver disease) could save lives. Current methods like checking bilirubin levels or stool color show promise for early detection and improved outcomes in infants.
Area of Science:
- Pediatrics
- Hepatology
- Public Health
Background:
- Biliary atresia is a primary cause of pediatric end-stage liver disease.
- It is the leading reason for pediatric liver transplants.
- Early diagnosis and surgical intervention improve native liver survival.
Purpose of the Study:
- To assess the feasibility of newborn screening for biliary atresia in the United States.
- To evaluate current screening methods against established criteria.
- To determine if screening can improve infant outcomes.
Main Methods:
- Reviewed published analyses on newborn screening for biliary atresia.
- Assessed screening strategies using criteria from the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children.
- Examined the use of serum bilirubin concentrations and stool color cards.
Main Results:
- Newborn screening for biliary atresia using serum bilirubin or stool color cards is potentially life-saving.
- These screening methods appear to be cost-effective.
- Early identification of biliary atresia is crucial for better survival rates.
Conclusions:
- Newborn screening for biliary atresia warrants further investigation.
- Additional studies are needed to evaluate the feasibility, effectiveness, and costs of screening strategies.
- Early identification through screening can significantly improve outcomes for affected infants.
Abstract:
Biliary atresia is the most common cause of pediatric end-stage liver disease and the leading indication for pediatric liver transplantation. Affected infants exhibit evidence of biliary obstruction within the first few weeks after birth. Early diagnosis and successful surgical drainage of bile are associated with greater survival with the child's native liver. Unfortunately, because noncholestatic jaundice is extremely common in early infancy, it is difficult to identify the rare infant with cholestatic jaundice who has biliary atresia. Hence, the need for timely diagnosis of this disease warrants a discussion of the feasibility of screening for biliary atresia to improve outcomes. Herein, newborn screening for biliary atresia in the United States is assessed by using criteria established by the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children. Published analyses indicate that newborn screening for biliary atresia by using serum bilirubin concentrations or stool color cards is potentially life-saving and cost-effective. Further studies are necessary to evaluate the feasibility, effectiveness, and costs of potential screening strategies for early identification of biliary atresia in the United States.
